Surgery Partners, Inc. SGRY
SGRY among the 162 companies we cover
Where it stands · the better end on the right. The band holds the middle half; the line is the median.
SGRY and 9 peers, year by year
The 9 Health care companies closest to SGRY in revenue over the last twelve months. Every number is from the 10-K and links to it in SEC's Inline XBRL viewer.
Choose the peers
| Company | Year | Revenue | Sales growth | Gross margin | Operating margin | Net margin | FCF margin | Return on equity | Debt / equity |
|---|---|---|---|---|---|---|---|---|---|
| SGRY Surgery Partners, Inc. | FY2025 | $3.3B | +6.2% | - | 11.8% | −2.4% | 5.9% | −4.5% | 2.18 |
| WST West Pharmaceutical Services | FY2025 | $3.1B | +6.3% | 35.9% | 19.0% | 16.1% | 15.3% | 15.5% | 0.06 |
| ACHC Acadia Healthcare Company, Inc. | FY2025 | $3.3B | +5.0% | - | - | −33.3% | −13.3% | −56.6% | 1.28 |
| VEEV Veeva Systems | FY2026 | $3.2B | +16.3% | 75.5% | 28.7% | 28.4% | - | 12.6% | - |
| AMRX Amneal Pharmaceuticals, Inc. | FY2025 | $3.0B | +8.0% | 36.9% | 13.1% | 2.4% | 8.9% | n/m | n/m |
| PODD Insulet Corporation | FY2025 | $2.7B | +30.7% | 71.6% | 17.5% | 9.1% | 13.9% | 16.3% | 0.63 |
| UTHR UNITED THERAPEUTICS Corp | FY2025 | $3.2B | +10.6% | 87.9% | 46.9% | 41.9% | 32.7% | 18.8% | - |
| XRAY DENTSPLY SIRONA Inc. | FY2025 | $3.7B | −3.0% | 50.0% | −11.5% | −16.2% | 2.8% | −44.7% | 1.76 |
| GMED Globus Medical Inc | FY2025 | $2.9B | +16.7% | - | 16.3% | 18.3% | 20.0% | 11.8% | - |
| BMRN Biomarin Pharmaceutical Inc | FY2025 | $3.2B | +12.9% | - | 12.7% | 10.8% | 22.5% | 5.7% | 0.10 |
Each company, year by year
Bars: revenue, each company on its own scale. Line: net margin, on one scale for all. FY2015 to FY2025 · 10-K XBRL
Who rewrote the most
Share of the words changed in Risk Factors and in MD&A, latest 10-K against the one before
Revenue, FY2015 to FY2025
Revenue as reported in the 10-K.
| Company | FY2015 | FY2016 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| SGRY Dec | $959.9M | $1.1B | $1.8B | $1.8B | $1.9B | $2.2B | $2.5B | $2.7B | $3.1B | $3.3B |
| WST Dec | $1.4B | $1.5B | $1.7B | $1.8B | $2.1B | $2.8B | $2.9B | $2.9B | $2.9B | $3.1B |
| ACHC Dec | - | $2.8B | $1.9B | $2.0B | $2.1B | $2.3B | $2.6B | $2.9B | $3.2B | $3.3B |
| VEEV Jan | - | $409.2M | $690.6M | $862.2M | $1.1B | $1.5B | $1.9B | $2.2B | $2.4B | $2.7B |
| AMRX Dec | - | $1.0B | $1.7B | $1.6B | $2.0B | $2.1B | $2.2B | $2.4B | $2.8B | $3.0B |
| PODD Dec | $263.9M | $367.0M | $563.8M | $738.2M | $904.4M | $1.1B | $1.3B | $1.7B | $2.1B | $2.7B |
| UTHR Dec | $1.5B | $1.6B | $1.6B | $1.4B | $1.5B | $1.7B | $1.9B | $2.3B | $2.9B | $3.2B |
| XRAY Dec | $2.7B | $3.7B | $4.0B | $4.0B | $3.3B | $4.2B | $3.9B | $4.0B | $3.8B | $3.7B |
| GMED Dec | $544.8M | $564.0M | $713.0M | $785.4M | $789.0M | $958.1M | $1.0B | $1.6B | $2.5B | $2.9B |
| BMRN Dec | $889.9M | $1.1B | $1.5B | $1.7B | $1.9B | $1.8B | $2.1B | $2.4B | $2.9B | $3.2B |
| Peer median | $1.1B | $1.1B | $1.6B | $1.6B | $1.9B | $1.8B | $2.1B | $2.4B | $2.9B | $3.1B |
Sales growth, FY2015 to FY2025
Revenue against the fiscal year before.
| Company | FY2015 | FY2016 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| SGRY Dec | +138% | +19.3% | - | +3.4% | +1.6% | +19.6% | +14.1% | +8.0% | +13.5% | +6.2% |
| WST Dec | - | +7.8% | +7.4% | +7.1% | +16.7% | +31.9% | +2.0% | +2.2% | −1.9% | +6.3% |
| ACHC Dec | - | - | +6.2% | +5.4% | +4.1% | +10.7% | +12.8% | +12.2% | +7.7% | +5.0% |
| VEEV Jan | - | - | +25.4% | +24.9% | +28.1% | +32.7% | +26.3% | +16.4% | +9.7% | +16.2% |
| AMRX Dec | - | - | +60.9% | −2.2% | +22.5% | +5.1% | +5.7% | +8.2% | +16.7% | +8.0% |
| PODD Dec | - | +39.1% | +21.6% | +30.9% | +22.5% | +15.1% | +18.8% | +30.0% | +22.1% | +30.7% |
| UTHR Dec | - | +9.1% | −5.7% | −11.0% | +2.4% | +13.6% | +14.9% | +20.2% | +23.6% | +10.6% |
| XRAY Dec | - | +40.0% | −0.2% | +1.1% | −17.0% | +26.7% | −7.3% | +1.1% | −4.3% | −3.0% |
| GMED Dec | - | +3.5% | +12.1% | +10.2% | +0.5% | +21.4% | +6.8% | +53.3% | +60.6% | +16.7% |
| BMRN Dec | - | +25.5% | +13.5% | +14.3% | +9.2% | −0.8% | +13.5% | +15.4% | +18.0% | +12.9% |
| Peer median | - | +17.3% | +12.1% | +7.1% | +9.2% | +15.1% | +12.8% | +15.4% | +16.7% | +10.6% |
Gross margin, FY2015 to FY2025
Gross profit / revenue.
| Company | FY2015 | FY2016 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| SGRY Dec | - | - | - | - | - | - | - | - | - | - |
| WST Dec | 32.6% | 33.2% | 31.8% | 32.9% | 35.8% | 41.5% | 39.4% | 38.3% | 34.5% | 35.9% |
| ACHC Dec | - | - | - | - | - | - | - | - | - | - |
| VEEV Jan | - | 65.2% | 69.4% | 71.6% | 72.5% | 72.1% | 72.8% | 71.7% | 71.3% | 74.5% |
| AMRX Dec | - | 58.7% | 43.1% | 21.7% | 31.5% | 36.7% | 35.5% | 34.3% | 36.5% | 36.9% |
| PODD Dec | 50.5% | 57.5% | 65.7% | 65.1% | 64.4% | 68.4% | 61.7% | 68.3% | 69.8% | 71.6% |
| UTHR Dec | - | - | - | 91.9% | 92.7% | 92.7% | 92.2% | 88.9% | 89.2% | 87.9% |
| XRAY Dec | 56.7% | 53.4% | 51.9% | 53.8% | 49.6% | 55.5% | 54.2% | 52.6% | 51.6% | 50.0% |
| GMED Dec | 75.7% | 76.1% | 77.6% | 77.1% | 72.4% | 75.0% | 74.2% | 65.1% | - | - |
| BMRN Dec | - | - | - | - | - | - | - | - | - | - |
| Peer median | 53.6% | 58.1% | 58.8% | 65.1% | 64.4% | 68.4% | 61.7% | 65.1% | 60.7% | 60.8% |
Operating margin, FY2015 to FY2025
Operating income / revenue.
| Company | FY2015 | FY2016 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| SGRY Dec | 15.1% | 17.2% | 4.4% | 12.9% | 9.8% | 13.6% | 13.6% | 12.0% | 11.2% | 11.8% |
| WST Dec | 9.2% | 12.9% | 14.0% | 16.1% | 19.0% | 26.6% | 25.4% | 22.9% | 19.7% | 19.0% |
| ACHC Dec | - | 21.7% | 31.2% | 29.2% | - | - | - | - | - | - |
| VEEV Jan | - | 19.2% | 22.9% | 25.8% | 25.9% | 25.8% | 27.3% | 21.3% | 18.2% | 25.2% |
| AMRX Dec | - | 28.0% | −1.2% | −15.3% | 4.6% | 7.3% | −4.3% | 8.5% | 8.9% | 13.1% |
| PODD Dec | −18.5% | −2.9% | 4.9% | 6.8% | 5.7% | 11.5% | 2.9% | 13.0% | 14.9% | 17.5% |
| UTHR Dec | 47.7% | 66.4% | 49.5% | −12.9% | 40.0% | 33.0% | 50.6% | 50.9% | 47.9% | 46.9% |
| XRAY Dec | 14.0% | 12.1% | −24.0% | 8.8% | −0.1% | 14.4% | −23.9% | −2.1% | −23.2% | −11.5% |
| GMED Dec | 31.6% | 27.3% | 23.7% | 21.9% | 14.1% | 17.9% | 22.3% | 8.5% | 6.6% | 16.3% |
| BMRN Dec | −12.4% | −71.9% | −8.3% | −5.9% | −2.3% | −4.5% | 7.7% | 7.7% | 17.0% | 12.7% |
| Peer median | 11.6% | 19.2% | 14.0% | 8.8% | 9.9% | 16.2% | 15.0% | 10.8% | 15.9% | 16.9% |
Net margin, FY2015 to FY2025
Net income / revenue.
| Company | FY2015 | FY2016 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| SGRY Dec | 0.1% | 0.8% | −11.6% | −4.1% | −6.2% | −3.2% | −2.2% | −0.4% | −5.4% | −2.4% |
| WST Dec | 6.8% | 9.5% | 12.0% | 13.1% | 16.1% | 23.4% | 20.3% | 20.1% | 17.0% | 16.1% |
| ACHC Dec | - | 0.2% | −9.2% | 5.4% | −32.2% | 8.2% | 10.5% | −0.7% | 8.1% | −33.3% |
| VEEV Jan | - | 13.3% | 21.9% | 26.7% | 27.3% | 25.9% | 23.1% | 22.6% | 22.2% | 26.0% |
| AMRX Dec | - | 0.0% | −1.2% | −37.1% | 3.4% | 0.6% | −12.2% | −3.5% | −4.2% | 2.4% |
| PODD Dec | −27.9% | −7.9% | 0.6% | 1.6% | 0.8% | 1.5% | 0.4% | 12.2% | 20.2% | 9.1% |
| UTHR Dec | 44.5% | 44.6% | 36.2% | −7.2% | 34.7% | 28.2% | 37.6% | 42.3% | 41.5% | 41.9% |
| XRAY Dec | 9.4% | 11.5% | −25.4% | 6.4% | −2.2% | 9.7% | −24.2% | −3.3% | −24.0% | −16.2% |
| GMED Dec | 20.7% | 18.5% | 21.9% | 19.8% | 13.0% | 15.6% | 18.6% | 7.8% | 4.1% | 18.3% |
| BMRN Dec | −19.3% | −56.4% | −5.2% | −1.4% | 45.9% | −3.5% | 6.8% | 6.9% | 15.0% | 10.8% |
| Peer median | 8.1% | 9.5% | 0.6% | 5.4% | 13.0% | 9.7% | 10.5% | 7.8% | 15.0% | 10.8% |
Free cash flow, FY2015 to FY2025
Cash from operations minus capital spending.
| Company | FY2015 | FY2016 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| SGRY Dec | $51.0M | $86.1M | $104.8M | $55.9M | $204.0M | $29.5M | $78.2M | $205.0M | $209.7M | $195.6M |
| WST Dec | $80.8M | $49.2M | $183.9M | $240.8M | $298.1M | $330.6M | $439.4M | $414.5M | $276.4M | $468.9M |
| ACHC Dec | −$35.6M | $54.0M | $160.9M | $100.2M | $433.8M | $129.7M | $84.4M | $38.2M | −$560.7M | −$439.9M |
| VEEV Jan | - | $59.0M | $223.8M | $302.4M | $434.3M | - | - | - | - | - |
| AMRX Dec | - | −$7.7M | $167.1M | −$45.5M | $322.6M | $194.1M | $18.7M | $302.4M | $243.2M | $269.9M |
| PODD Dec | −$23.2M | −$6.2M | −$121.5M | −$65.3M | −$45.0M | −$180.0M | −$3.9M | $70.1M | $305.3M | $377.7M |
| UTHR Dec | $333.0M | $605.6M | $594.0M | −$290.3M | $696.4M | $477.4M | $663.7M | $747.6M | $1.1B | $1.0B |
| XRAY Dec | $425.4M | $438.4M | $317.0M | $516.0M | $562.0M | $515.0M | $368.0M | $228.0M | $281.0M | $104.0M |
| GMED Dec | $73.2M | $106.9M | $121.9M | $101.2M | $135.1M | $219.4M | $104.4M | $165.2M | $405.2M | $588.8M |
| BMRN Dec | −$447.2M | −$376.2M | −$124.4M | −$96.8M | −$28.9M | $209.0M | $54.9M | $62.6M | $487.4M | $725.0M |
| Peer median | $73.2M | $54.0M | $167.1M | $100.2M | $322.6M | $214.2M | $94.4M | $196.6M | $293.1M | $423.3M |
FCF margin, FY2015 to FY2025
Free cash flow / revenue.
| Company | FY2015 | FY2016 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| SGRY Dec | 5.3% | 7.5% | 5.9% | 3.1% | 11.0% | 1.3% | 3.1% | 7.5% | 6.7% | 5.9% |
| WST Dec | 5.8% | 3.3% | 10.7% | 13.1% | 13.9% | 11.7% | 15.2% | 14.1% | 9.6% | 15.3% |
| ACHC Dec | - | 1.9% | 8.4% | 5.0% | 20.8% | 5.6% | 3.2% | 1.3% | −17.8% | −13.3% |
| VEEV Jan | - | 14.4% | 32.4% | 35.1% | 39.3% | - | - | - | - | - |
| AMRX Dec | - | −0.8% | 10.1% | −2.8% | 16.2% | 9.3% | 0.8% | 12.6% | 8.7% | 8.9% |
| PODD Dec | −8.8% | −1.7% | −21.6% | −8.8% | −5.0% | −16.4% | −0.3% | 4.1% | 14.7% | 13.9% |
| UTHR Dec | 22.7% | 37.9% | 36.5% | −20.0% | 46.9% | 28.3% | 34.3% | 32.1% | 37.6% | 32.7% |
| XRAY Dec | 15.9% | 11.7% | 8.0% | 12.8% | 16.8% | 12.2% | 9.4% | 5.8% | 7.4% | 2.8% |
| GMED Dec | 13.4% | 19.0% | 17.1% | 12.9% | 17.1% | 22.9% | 10.2% | 10.5% | 16.1% | 20.0% |
| BMRN Dec | −50.2% | −33.7% | −8.3% | −5.7% | −1.6% | 11.3% | 2.6% | 2.6% | 17.1% | 22.5% |
| Peer median | 9.6% | 3.3% | 10.1% | 5.0% | 16.8% | 11.5% | 6.3% | 8.1% | 12.1% | 14.6% |
Return on equity, FY2015 to FY2025
Net income / shareholders' equity at the year end.
| Company | FY2015 | FY2016 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| SGRY Dec | n/m | 97.7% | −50.8% | −25.2% | −100.4% | −6.5% | −2.7% | −0.6% | −9.4% | −4.5% |
| WST Dec | 9.3% | 12.9% | 14.8% | 15.4% | 18.7% | 28.3% | 21.8% | 20.6% | 18.4% | 15.5% |
| ACHC Dec | 6.7% | 0.3% | −7.5% | 4.3% | −35.4% | 7.6% | 9.7% | −0.8% | 8.3% | −56.6% |
| VEEV Jan | - | 10.4% | 16.7% | 18.6% | 18.1% | 16.8% | 14.7% | 13.1% | 11.3% | 12.2% |
| AMRX Dec | - | - | −3.9% | n/m | 22.4% | 3.7% | −90.7% | n/m | n/m | n/m |
| PODD Dec | n/m | −45.8% | 1.6% | 15.3% | 1.1% | 3.0% | 1.0% | 28.2% | 34.5% | 16.3% |
| UTHR Dec | 41.0% | 38.6% | 21.1% | −3.8% | 15.2% | 12.0% | 15.2% | 16.5% | 18.5% | 18.8% |
| XRAY Dec | 10.7% | 5.3% | −19.7% | 5.0% | −1.5% | 8.2% | −24.9% | −4.0% | −46.9% | −44.7% |
| GMED Dec | 15.8% | 12.5% | 13.2% | 11.1% | 6.8% | 8.6% | 10.3% | 3.1% | 2.5% | 11.8% |
| BMRN Dec | −7.2% | −22.8% | −2.6% | −0.8% | 20.8% | −1.5% | 3.1% | 3.4% | 7.5% | 5.7% |
| Peer median | 10.0% | 7.9% | 1.6% | 8.0% | 15.2% | 8.2% | 9.7% | 8.3% | 9.8% | 12.0% |
Debt / equity, FY2015 to FY2025
Total debt / shareholders' equity at the year end.
| Company | FY2015 | FY2016 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| SGRY Dec | n/m | n/m | 5.75 | 8.75 | n/m | 2.72 | 1.32 | 1.41 | 1.90 | 2.18 |
| WST Dec | 0.36 | 0.21 | 0.14 | 0.16 | 0.14 | 0.11 | 0.08 | 0.07 | 0.08 | 0.06 |
| ACHC Dec | 1.33 | 1.52 | 1.37 | 1.26 | 1.64 | 0.59 | 0.49 | 0.49 | 0.64 | 1.28 |
| VEEV Jan | - | - | - | - | - | - | - | - | - | - |
| AMRX Dec | - | - | 5.25 | 11.34 | 9.17 | 7.52 | 8.79 | n/m | n/m | n/m |
| PODD Dec | 5.04 | 5.27 | 2.79 | 11.70 | 1.75 | 2.29 | 2.94 | 1.93 | 1.14 | 0.63 |
| UTHR Dec | - | - | - | - | - | - | - | - | - | - |
| XRAY Dec | 0.49 | 0.19 | 0.32 | 0.28 | 0.46 | 0.42 | 0.52 | 0.65 | 1.12 | 1.76 |
| GMED Dec | - | - | - | - | - | - | - | - | - | - |
| BMRN Dec | - | - | - | - | - | - | - | - | - | 0.10 |
| Peer median | 0.91 | 0.86 | 1.37 | 1.26 | 1.64 | 0.59 | 0.52 | 0.57 | 0.88 | 0.63 |
EPS (diluted), FY2015 to FY2025
Diluted earnings per share, on today's share count after splits.
| Company | FY2015 | FY2016 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| SGRY Dec | $0.04 | $0.20 | −$4.96 | −$2.29 | −$3.19 | −$1.12 | −$0.59 | −$0.09 | −$1.33 | −$0.61 |
| WST Dec | $1.30 | $1.91 | $2.74 | $3.21 | $4.57 | $8.67 | $7.73 | $7.88 | $6.69 | $6.79 |
| ACHC Dec | $1.64 | $0.07 | −$2.01 | $1.24 | −$7.59 | $2.10 | $2.98 | −$0.24 | $2.78 | −$12.16 |
| VEEV Jan | - | $0.38 | $0.98 | $1.47 | $1.90 | $2.36 | $2.63 | $3.00 | $3.22 | $4.32 |
| AMRX Dec | - | - | −$0.16 | −$2.74 | $0.61 | $0.07 | −$0.86 | −$0.48 | −$0.38 | $0.22 |
| PODD Dec | −$1.29 | −$0.48 | $0.05 | $0.19 | $0.10 | $0.24 | $0.07 | $2.94 | $5.78 | $3.48 |
| UTHR Dec | $12.72 | $15.25 | $13.39 | −$2.39 | $11.54 | $10.06 | $15.00 | $19.81 | $24.64 | $27.86 |
| XRAY Dec | $1.76 | $1.94 | −$4.51 | $1.14 | −$0.33 | $1.87 | −$4.41 | −$0.62 | −$4.48 | −$3.00 |
| GMED Dec | $1.17 | $1.08 | $1.54 | $1.52 | $1.01 | $1.44 | $1.85 | $1.07 | $0.75 | $3.92 |
| BMRN Dec | −$1.07 | −$3.81 | −$0.44 | −$0.13 | $4.50 | −$0.35 | $0.75 | $0.87 | $2.21 | $1.80 |
| Peer median | $1.30 | $0.73 | $0.05 | $1.14 | $1.01 | $1.87 | $1.85 | $1.07 | $2.78 | $3.48 |
Fiscal years are lined up as each company's 10-K names them; the month next to a ticker is when its year ends. Hover a number for the XBRL line items and the filing; click it to open the filing on sec.gov. "n/m" means not meaningful: equity below zero, or a base so close to zero that the ratio says nothing. The peer median leaves out SGRY and needs at least three peers with the number. P/E, P/S and P/FCF at each year end appear here once the site has daily prices. What the same companies write about AI, tariffs and more
Sources
Each company's 10-K, from SEC's XBRL company facts. Every number links to its filing in the Inline XBRL viewer.
Also
Financials: SGRY's own statements, year by year. Compare: the whole peer group on one page.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/SGRY/export.csv") into a cell.